Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment

43Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Osteoporosis is a key health problem in postmenopausal women with high social and economic impact. Decreased bone mineral density (BMD) and deterioration of bone microarchitecture may occur also as a result of long-term glucocorticoid treatment (GCT) of autoimmune or inflammatory conditions. Denosumab specifically inhibits the binding of the receptor activator of nuclear factor-kB to its ligand, thus preventing osteoclast activation and bone resorption. The efficacy and safety of denosumab, administered subcutaneously as 60 mg, once every six months for 12 months, were evaluated in 60 patients with postmenopausal osteoporosis (PMO) divided into two groups. The GCT group included 30 patients receiving concomitant glucocorticoid therapy and the non-GCT group included 30 patients that did not receive GCT. In the non-GCT group, the 12-month treatment with denosumab resulted in BMD increase of 6.1% and 2.8% in lumbar spine and hip, respectively. T-score increased by 13.1% and 5.6% in both, the lumbar spine and hip. A slight rise in the Trabecular Bone Score (TBS) of 0.3% was observed. Bone pain was markedly reduced by 56.2%. In the GCT group, denosumab therapy increased BMD with 5.8% and 2.3% in lumbar spine and hip, respectively. T-score of lumbar spine and hip significantly increased by 14.0% and 4.4%, and the TBS rose by 5%. Bone pain was reduced by 53.6%. These data confirm the available knowledge on denosumab efficacy and safety in women with PMO and also provide new insights into its therapeutic potential in patients with osteoporosis related to a long-term corticosteroid treatment.

References Powered by Scopus

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

4830Citations
N/AReaders
Get full text

Osteoprotegerin: A novel secreted protein involved in the regulation of bone density

4565Citations
N/AReaders
Get full text

Glucocorticoid-induced osteoporosis: Pathophysiology and therapy

939Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice

127Citations
N/AReaders
Get full text

Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

94Citations
N/AReaders
Get full text

The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice

90Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Petranova, T., Sheytanov, I., Monov, S., Nestorova, R., & Rashkov, R. (2014). Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnology and Biotechnological Equipment, 28(6), 1127–1137. https://doi.org/10.1080/13102818.2014.967827

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

73%

Researcher 3

14%

Professor / Associate Prof. 2

9%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

88%

Engineering 1

4%

Environmental Science 1

4%

Psychology 1

4%

Save time finding and organizing research with Mendeley

Sign up for free